18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

Recruiting now

Conditions studied: Tuberculosis, Pulmonary

In brief

The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed patients with active tuberculosis will be invited to participate in the study. A whole-body PET scan will be performed after 18F-FAPI-74 intravenous injection and correlation will be made with sites of TB lesions noted on CT. It is anticipated that 18F-FAPI-74 PET will be able to detect fibrosis (with high sensitivity) in the TB lesions.

Key facts

Study ID
NCT07077213
Run by
Children's Hospital Medical Center, Cincinnati
People needed
30
Starts
2026-03-12
Expected to finish
2027-12-01
Last updated by the study team
2026-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.